Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › clopidogrel

clopidogrel

22 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of clopidogrel

80 trials tracked of clopidogrel: 49 in phase 3 or 4 and 18 with published results. The most-cited published study has 1514 citations.

80Trials tracked
49Phase 3 & 4
0Recruiting
18With published results
Phase distribution
Phase 4 32 Phase 3 17 Phase 2 18 Phase 1 9 Other / NA 4
  1. Phase 4 Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study) Completed · 1,514 cited
  2. Phase 3 Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Completed · 683 cited
  3. Phase 4 Tailored Antiplatelet Therapy Following PCI Completed · 421 cited
  4. Phase 3 Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) Completed · 287 cited
  5. Phase 4 Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial Completed · 84 cited
  6. Phase 3 A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention Completed · 76 cited
Show 44 more trials
  1. Phase 4 Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease Completed · 59 cited
  2. Phase 4 STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction Completed · 55 cited
  3. Phase 3 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation Completed · 50 cited
  4. Phase 4 Ranitidin Versus Omeprazole in Patients Taking Clopidogrel Completed · 26 cited
  5. Phase 4 Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus Completed · 19 cited
  6. Phase 3 A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease Completed · 17 cited
  7. Phase 4 Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI Completed · 16 cited
  8. Phase 4 Clopidogrel and Aspirin Interaction Study-2 Completed · 11 cited
  9. Phase 4 Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Completed · 10 cited
  10. Phase 3 STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction Completed · 7 cited
  11. Phase 4 Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus Completed · 3 cited
  12. Phase 4 Clopidogrel Monotherapy in Patients With High Bleeding Risk Completed · 2 cited
  13. Phase 4 Pharmacogenomics of Antiplatelet Response - I Completed
  14. Phase 4 Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation Completed
  15. Phase 4 Clopidogrel Versus Ticagrelor in Type-2 Diabetes Completed
  16. Phase 4 Antiplatelet Therapy After Cardiac Arrest Completed
  17. Phase 4 P3AMI Antiplatelet Trial Completed
  18. Phase 4 Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction Completed
  19. Phase 4 Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI Completed
  20. Phase 4 Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR) Completed
  21. Phase 4 CES1 Carriers in the PAPI Study Completed
  22. Phase 4 CES1 Crossover Trial of Clopidogrel and Ticagrelor Completed
  23. Phase 4 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II Completed
  24. Phase 4 PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes Completed
  25. Phase 4 Investigation of the Athero-Protective Effects of Clopidogrel Completed
  26. Phase 4 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study) Completed
  27. Phase 4 A Pharmacodynamic Study With Ticagrelor in Hispanic Patients Completed
  28. Phase 4 Prasugrel/Clopidogrel Maintenance Dose Washout Study Completed
  29. Phase 4 A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS Completed
  30. Phase 4 A Pharmacodynamic Study With Ticagrelor in African American Patients Completed
  31. Phase 4 The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease Completed
  32. Phase 4 Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients Completed
  33. Phase 3 Efficacy and Safety of Low-dose Ticagrelor Completed
  34. Phase 3 Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities Completed
  35. Phase 3 Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation Completed
  36. Phase 3 A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome Completed
  37. Phase 3 Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS Completed
  38. Phase 3 Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) Completed
  39. Phase 3 Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry Completed
  40. Phase 3 A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention Completed
  41. Phase 3 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events Completed
  42. Phase 3 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome Completed
  43. Phase 3 A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects Completed
  44. Phase 2 Cangrelor to Clopidogrel or Prasugrel Transition Study Completed

Showing the 50 most-cited and recently-updated of 80 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Low Dose Ticagrelor and Aspirin Reduce Early Neurological Deterioration in Ischemic Stroke
Neurology RCT
Low Dose Ticagrelor and Aspirin Reduce Early Neurological Deterioration in Ischemic Stroke Trial shows ticagrelor and aspirin may reduce neurological decline
A randomized trial suggests that low-dose ticagrelor combined with aspirin significantly reduces early neurological deterioration in high-ri…
A new clinical trial suggests that a specific combination of ticagrelor and aspirin may help prevent early neurological decline after a stro…
Sep 10, 2026
Bayesian analysis of P2Y12 inhibitors identifies clinical uncertainties and equivalence in acute coronary syndromes
Cardiology Meta-analysis
Bayesian analysis of P2Y12 inhibitors identifies clinical uncertainties and equivalence in acute coronary syndromes Trial Shows Prasugrel May Offer Benefits Over Clopidogrel for Heart Patients
This meta-analysis of 60,619 patients following percutaneous coronary intervention evaluates P2Y12 inhibitors using a Bayesian framework. Th…
A large analysis of over 60,000 patients suggests prasugrel may be more effective than clopidogrel for preventing major heart events after p…
medRxiv Sep 7, 2026
Clopidogrel monotherapy reduces bleeding risk to 2.1% versus 3.2% in patients with acute coronary syndromes
Diabetes & Endocrinology RCT
Clopidogrel monotherapy reduces bleeding risk to 2.1% versus 3.2% in patients with acute coronary syndromes Trial shows clopidogrel alone reduces bleeding risk after heart procedures
This prespecified subgroup analysis of a randomized controlled trial involving 7758 patients with acute coronary syndromes found that clopid…
Patients with heart conditions may face fewer bleeding risks by switching to clopidogrel alone after a period of dual therapy.
Sep 4, 2026
Clopidogrel plus aspirin for 21 days provides favorable net clinical benefit in minor ischemic stroke
Neurology Sys. Review
Clopidogrel plus aspirin for 21 days provides favorable net clinical benefit in minor ischemic stroke Dual antiplatelet therapy shows mixed results for stroke prevention
This Bayesian network meta-analysis of 8 trials involving 50,349 adults with minor ischemic stroke or high-risk TIA found that clopidogrel p…
New data compares different blood thinner combinations to find the best way to prevent a second stroke after a minor medical emergency.
Sep 1, 2026
NOAC monotherapy reduces net adverse clinical events in older patients with atrial fibrillation and stents
Cardiology RCT
NOAC monotherapy reduces net adverse clinical events in older patients with atrial fibrillation and stents NOAC Monotherapy Shows Lower Risk for Older Patients with Atrial Fibrillation
This post hoc analysis investigated the impact of NOAC monotherapy versus combination therapy with clopidogrel in patients with atrial fibri…
Patients over 75 with atrial fibrillation and drug-eluting stents may have fewer adverse events when taking a single NOAC instead of combina…
Aug 5, 2026
Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patients
Cardiology Meta-analysis
Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patients Ticagrelor Shows Lower Mortality Risk Than Clopidogrel for Heart Patients
This meta-analysis of 31,729 adult STEMI patients post-PCI found that ticagrelor significantly reduced all-cause mortality (OR = 0.64) and m…
A large analysis of over 31,000 patients suggests ticagrelor may lower mortality and heart attack risks compared to clopidogrel after a hear…
NEJM Jul 26, 2026
Lower aspirin doses combined with clopidogrel may reduce ischemic events in high risk patients
Cardiology RCT
Lower aspirin doses combined with clopidogrel may reduce ischemic events in high risk patients Lower Aspirin Doses May Be Safer for Patients After Minor Strokes
Researchers analyzed data from a trial involving patients with transient ischemic attack and minor stroke receiving dual antiplatelet therap…
Doctors found that taking a lower dose of aspirin with clopidogrel may reduce the risk of serious heart and brain events.
Jul 21, 2026
Extended DAPT with clopidogrel and aspirin reduces cardiovascular death, myocardial infarction, and stroke risk
Cardiology RCT
Extended DAPT with clopidogrel and aspirin reduces cardiovascular death, myocardial infarction, and stroke risk Extended dual antiplatelet therapy lowers risks for heart disease patients
This randomized trial of 8250 patients with multivessel coronary artery disease found that extending dual antiplatelet therapy (DAPT) for an…
Patients with coronary artery disease may have lower risks of stroke and heart attack when taking two blood thinners for an extra year.
Jul 16, 2026
General medical management improves medication adherence and lifestyle outcomes in older adults with type 2 diabetes
Diabetes & Endocrinology RCT
General medical management improves medication adherence and lifestyle outcomes in older adults with type 2 diabetes New management model improves medication use and health for seniors
This randomized controlled trial of 200 older adults with type 2 diabetes and atherosclerotic cardiovascular disease found that a general me…
A new personalized care plan helps older adults with diabetes and heart disease stay on their medications and improve their daily habits.
Jun 26, 2026
Tirofiban Adjunct Therapy Improves Outcomes in Patients with Inadequate Tenecteplase Response
Neurology RCT
Tirofiban Adjunct Therapy Improves Outcomes in Patients with Inadequate Tenecteplase Response Trial shows tirofiban improves outcomes for some stroke patients
Intravenous tirofiban significantly improves 90-day functional outcomes for acute ischemic stroke patients failing initial tenecteplase ther…
A new clinical trial suggests that adding tirofiban can improve recovery rates for certain types of stroke patients who do not respond well …
JAMA Jun 13, 2026
Pantoprazole exposure linked to insulin autoimmune syndrome in case report
Diabetes & Endocrinology Sys. Review
Pantoprazole exposure linked to insulin autoimmune syndrome in case report Stopping a stomach acid drug helped a patient with low blood sugar recover
This case report describes a patient with insulin autoimmune syndrome (IAS) temporally associated with pantoprazole exposure. Discontinuatio…
A patient with insulin autoimmune syndrome found relief when doctors stopped a common stomach acid medication, suggesting a possible link be…
Frontiers Jun 3, 2026
FDA approves ticagrelor for multiple indications in cardiology and neurology
Cardiology FDA Approval
FDA approves ticagrelor for multiple indications in cardiology and neurology Brilinta Now Approved for Stroke Prevention in Three Key Groups
The FDA approved ticagrelor (Brilinta) for patients with ACS, CAD at high risk, and acute ischemic stroke or high-risk TIA. In ACS, it was s…
A widely used heart medication now has FDA approval to prevent first strokes in people with diabetes and to protect against repeat strokes a…
FDA May 14, 2026

All clopidogrel Articles